过滤
关闭导航

索拉非尼 [索拉菲尼],Sorafenib;≥98% (HPLC)

别名:Raf抑制剂;4-[4-[[[[4-氯-3-(三氟甲基)苯基]氨基]羰基]氨基]苯氧基]-N-甲基-2-吡啶甲酰胺;4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide;BAY 43-9006;BAY43-9006;N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

Empirical Formula (Hill Notation): C21H16ClF3N4O3 CAS号: 284461-73-0 分子量: 464.82 MDL编号: MFCD06411450
制造商品牌: 西格玛 Sigma-Aldrich
货号(SKU): SML2653
CAS号: 284461-73-0
MDL号: MFCD06411450
签订合同 √ 正规发票 √ 技术支持 √ 质量保障 √ 全程可追溯 √
¥976.00

说明

索拉非尼(BAY 43-9006)是一种口服活性激酶抑制剂,通过靶向b-Raf,c-Raf(Raf-1)以及参与新生血管形成的几种受体酪氨酸激酶,在体外和体内发挥广谱抗癌功效。和肿瘤进展,包括血管内皮生长因子受体2/3(VEGFR-2/Flk-1/KDR,VEGFR-3),血小板衍生的生长因子受体β(PDGFR-ß),Flt-3,c-KIT,FGFR-1(Flt-2)和RET。

生化/生理作用

Sorafenib (BAY 43-9006) is an orally active kinase inhibitor that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-ß), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.
 
 

属性

测定

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

InChI key

MLDQJTXFUGDVEO-UHFFFAOYSA-N

 

安全信息

象形图

Health hazardEnvironment

警示用语:

Danger

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

储存分类代码

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

商品规格
属性名称属性值
储存温度 Storage temp.2-8°C冷藏
全球实时库存 Availability √美国St. Louis ≥ 50 | 欧洲Eur. ≥ 12 | 東京Tokyo ≥ 20 | 香港与北京 ≥ 50
商品标签 [tags]